AstraZeneca lung cancer drug given green light in US

FDA approval of Tagrisso offers major boost for British company, seeking to release six new cancer medicines by 2020A new lung cancer pill from AstraZeneca has been approved by US regulators, in a major boost for the British drugmaker.AZD9291, which will be sold as Tagrisso, is for advanced non-small-cell lung cancer, the most common form of lung cancer. Tagrisso targets a genetic mutation, known as T790M, that helps tumours evade current lung cancer pills. The drug will be made available to patients in the US as soon as possible and its price will be “comparable to other oral cancer therapies,” a spokeswoman said. AstraZeneca will reveal the price early next week. Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: AstraZeneca Business Pharmaceuticals industry Cancer Health Society Medical research Source Type: news

Related Links:

Afatinib is an oral irreversible epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) indicated in first-line treatment of advanced EGFR-mutant (EGFRm+) non-small cell lung cancer (NSCLC). D...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Lung cancer is the most common cancer and the leading cause of cancer-related death worldwide [1]. Non-small cell lung cancer (NSCLC) accounts for 85% of new diagnosed cases. Most patients are diagnosed with an unresectable disease and about 22% have a locally advanced disease [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Tosedostat represents a next generation oral aminopeptidase inhibitor prodrug that has recently demonstrated promising activity in elderly patients with relapsed and refractory acute myeloid leukemia (AML). This prodrug is bio-activated to its hydrophilic active metabolite by intracellular esterases including carboxylesterase 1 (CES1) hence enhancing its cellular retention and promoting targeting of multiple aminopeptidases.Aminopeptidase inhibition provokes an amino acid deprivation response, inhibition of mTOR activity and blockade of protein synthesis. The fact that CES1 also has an important physiological function in c...
Source: Blood - Category: Hematology Authors: Tags: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III Source Type: research
Conclusion: Response to acalabrutinib remained consistent during long-term (>24-month) follow-up, including high response rates, median PFS of 19.5 months, and a median OS that has not yet been reached, confirming efficacy in patients with relapsed/refractory MCL. The AE profile was largely similar to earlier reporting, with limited additional safety events observed with an additional year of follow-up.DisclosuresWang: Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Dava Oncology: Honoraria; AstraZeneca: Consultancy, Research Funding; Pharmacyclics: Honoraria, R...
Source: Blood - Category: Hematology Authors: Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Poster II Source Type: research
ConclusionWe confirmed MOV as an extremely safe treatment in a large real world population of advanced NSCLC with an interesting activity mainly consisting of long-term disease stabilization. We speculate the possibility of a synergistic effect with subsequent immunotherapy.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Background: Erlotinib is used for treating non–small cell lung cancer (NSCLC). Intestinal absorption of erlotinib is impaired under gastric pH elevation; therefore, coadministration of gastric acid suppressants may provide lower blood concentration of erlotinib. We investigated the effects of erlotinib coadministration with proton pump inhibitors (PPIs) and histamine H2 receptor blockers (H2RBs) on the plasma concentration of erlotinib and erlotinib-induced adverse reaction in patients with NSCLC. Methods: Forty-two patients receiving erlotinib therapy for NSCLC were recruited for this study. Association of adve...
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Original Article Source Type: research
Conclusions: The 43% 1-year survival for patients receiving bexarotene with weekly paclitaxel and monthly carboplatin is encouraging. With the availability of new classes of agents for lung cancer, further evaluation of this regimen in unselected patients is not warranted. Our study confirms prior subgroup analyses showing a significant correlation between bexarotene-induced hypertriglyceridemia and survival. Further research is needed to identify molecular biomarkers to identify this subset of patients and to explore rexinoids in other combinations, especially with immunotherapy. PMID: 30416803 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
This study supports the use of intravenous dexamethasone 10 mg before pemetrexed infusion in place of three days of oral dexamethasone 4 mg twice daily at UNMCCC,” the authors wrote. The post Alimta-Related Skin Reactions with and Without Oral Steroids appeared first on Mesothelioma Center - Vital Services for Cancer Patients &Families.
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsSingle ‐agent nab‐paclitaxel was associated with promising outcomes and a tolerable safety profile as second‐line treatment for patients with advanced‐stage, nonsquamous non‐small cell lung cancer. There was no benefit from the addition of CC‐486 to nab‐paclitaxel.
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
In conclusion, alternate-day S-1 administration can be a safe treatment regimen for elderly patients with NSCLC, but its therapeutic efficacy and safety for elderly patients with NSCLC should be compared against the standard S-1 administration in a large-scale study. PMID: 30345049 [PubMed]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
More News: AstraZeneca | Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Health | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Research | Science